<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05033704</url>
  </required_header>
  <id_info>
    <org_study_id>MRC-01-18-256</org_study_id>
    <nct_id>NCT05033704</nct_id>
  </id_info>
  <brief_title>Effect of Human Plasma Protein Transfusion With and Without Crystalloids During Major Liver Resection Surgeries</brief_title>
  <official_title>Effect of Human Plasma Protein Transfusion With and Without Crystalloids on Acid Base, Electrolytes and Tissue Perfusion During Major Liver Resection Surgeries</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hamad Medical Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hamad Medical Corporation</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Evaluation of acid-base and electrolyte changes after administration of commonly used colloid&#xD;
      solutions (plasma protein fraction contains 5% albumin), and crystalloids (saline 0.9% and&#xD;
      lactated ringers solutions) is the primary endpoint of this study. The secondary endpoints&#xD;
      are to study dilution acidosis and changes in plasma volume induced by albumin versus&#xD;
      crystalloids and their effect on tissue perfusion by randomizing patients into two groups&#xD;
      where each group receives intraoperatively one type of the two fluids. Changes in acid-base,&#xD;
      electrolytes, and dilution acidosis&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To compare Between PPF 5% and crystalloids in the management of patients undergoing Liver&#xD;
      resection and to conclude if any the benefits of treating those patients with high protein&#xD;
      content fluids.&#xD;
&#xD;
      Methodology: Each patient will complete a full medical and surgical history and clinical&#xD;
      examination.&#xD;
&#xD;
      Routine examinations will include complete blood picture, kidney function tests (serum urea,&#xD;
      creatinine, sodium, and potassium), liver function tests (alanine transaminase, aspartate&#xD;
      transaminase, prothrombin time and concentration and international normalized ratio, and&#xD;
      serum albumin), random blood sugar, and serum electrolytes (Calcium, Chloride bicarbonate and&#xD;
      lactate). Patients will be distributed randomly between two groups using a predetermined&#xD;
      computer-generated randomized schedule. Twenty-four of the 48 patients will receive an&#xD;
      intraoperative intravenous infusion of 5% human plasma protein fraction PPF, (A group). PPF&#xD;
      5%?Octapharma 5 %? is a colloid solution containing (47.6-52.5% proteins, of which 45.6-52.5&#xD;
      gm/L albumin and 142.5-157.5 mmol/L sodium). The remaining 24 patients will receive an&#xD;
      intraoperative intravenous infusion of crystalloids (0.9 % normal saline and/ or Lactated&#xD;
      Ringer's solution) (RS group). Fluids will be given targeting euvolemic state which is&#xD;
      defined as central venous pressure (CVP) 5-10 mmHg or Stroke volume variation (SVV) of? 13%.&#xD;
      Central venous pressure (CVP) CVP of -1 to 1 mmHg or Stroke volume variation (SVV) of 18-21%&#xD;
      (12) will be targeted during transaction times.&#xD;
&#xD;
      The transfusion trigger will be Hemoglobin of? 8 gm/dl. Any patient who received additional&#xD;
      blood products will be excluded from the study. General anesthesia will be induced using&#xD;
      Propofol 2% and fentanyl. The ultrasound-guided central venous catheter will be inserted&#xD;
      after induction of anesthesia in the right internal jugular vein. Arterial Cather size&#xD;
      20-gauge will be inserted in the radial artery. All patients will receive inhalational&#xD;
      anesthesia using Sevoflurane, targeting MAC 1, and be ventilated using the Drager Xeus&#xD;
      machine. Tidal volume of 7ml/Kg and zero PEEP will be used for all patients. All patients&#xD;
      will receive furosemide 20-40 mg to maintain good diuresis and control central venous&#xD;
      pressure. In addition to this, a 30-45 degree head-up position will be maintained. Arterial&#xD;
      blood will be drawn through the radial artery catheter before the start of surgery and fluid&#xD;
      infusion (time 0), the start of liver resection (time R), after Liver resection (time AR),&#xD;
      and at the end of the procedure (time E). Arterial blood gas parameters (using atrial blood&#xD;
      gas analyzer machine) including, pH, K+, Cl-, HCO3-, base deficit, and lactate concentrations&#xD;
      will be measured. Hemoglobin, hematocrit concentrations, and albumin will be measured and&#xD;
      recorded at time 0, R, AR &amp; E. Intravascular albumin mass will be calculated based on plasma&#xD;
      volume (PV) which will be calculated according to Nadler's Formula for calculating total&#xD;
      blood volume in adult (TBV) (9, 14): PV = TBV ? (1 ? hematocrit)&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 9, 2019</start_date>
  <completion_date type="Anticipated">September 1, 2021</completion_date>
  <primary_completion_date type="Anticipated">September 1, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Base deficit</measure>
    <time_frame>Intra-operative at the end of the four stages of liver resection</time_frame>
    <description>The primary end point of the study will be changes in base deficit in the two groups</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Strong Ion difference</measure>
    <time_frame>Intra-operative time at the end of four stages of liver resection</time_frame>
    <description>The primary end point of the study will be changes in strong ion difference in the two groups</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Intra-vascular Albumin content</measure>
    <time_frame>Intra-operative time at the end of the four stages of liver resection</time_frame>
    <description>The primary end point of the study will be changes in intra-vascular albumin mass in the two groups</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Kidney functions</measure>
    <time_frame>Urine out put at the end of surgery and postoperative day one serum creatinine</time_frame>
    <description>Two group comparison on postoperative serum creatinine and urine output at the end of surgery</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total blood loss</measure>
    <time_frame>End of surgery blood loss</time_frame>
    <description>Comparing the two groups regarding intra-operative blood loss</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in coagulation using Thromboelastogram</measure>
    <time_frame>At the the end of resection phase and end of surgery</time_frame>
    <description>Comparing the coagulation of the two groups at the end of resection and end of surgery</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tissue perfusion index</measure>
    <time_frame>The four intra-operative stages of liver resection</time_frame>
    <description>statistically comparing tissue perfusion index between the two groups at the 4 surgical times</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">48</enrollment>
  <condition>Coagulation; Intravascular</condition>
  <condition>Fluid Electrolyte Disorders</condition>
  <arm_group>
    <arm_group_label>(Group A)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Twenty-four of the 48 patients will receive an intraoperative intravenous infusion of 5% human plasma protein fraction PPF, (A group). PPF 5% &quot;Octapharma 5 %&quot; is a colloid solution containing (47.6-52.5% proteins, of which 45.6-52.5 gm/L albumin and 142.5-157.5 mmol/L sodium).&#xD;
Fluids will be given targeting euvolemic state which is defined as central venous pressure (CVP) 5-10 mmHg or Stroke volume variation (SVV) of ≤ 13%. Central venous pressure (CVP) CVP of -1 to 1 mmHg or Stroke volume variation (SVV) of 18-21% (12) will be targeted during transaction times. The transfusion trigger will be Hemoglobin of ≤8 gm/dl.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>(Group RS)</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>24 patients will receive an intraoperative intravenous infusion of crystalloids (0.9 % normal saline and/ or Lactated Ringer's solution) (RS group). Fluids will be given targeting euvolemic state which is defined as central venous pressure (CVP) 5-10 mmHg or Stroke volume variation (SVV) of ≤ 13%. Central venous pressure (CVP) CVP of -1 to 1 mmHg or Stroke volume variation (SVV) of 18-21% (12) will be targeted during transaction times. The transfusion trigger will be Hemoglobin of ≤8 gm/dl.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>5% human plasma protein fraction (PPF)</intervention_name>
    <description>Infusion of 5% human plasma protein fraction PPF. PPF 5% &quot;Octapharma 5 %&quot; is a colloid solution containing (47.6-52.5% proteins, of which 45.6-52.5 gm/L albumin and 142.5-157.5 mmol/L sodium).</description>
    <arm_group_label>(Group A)</arm_group_label>
    <other_name>5% Human Albumen</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  18- 70 years old&#xD;
&#xD;
          -  Not allergic to PPF5%, NS and RL,&#xD;
&#xD;
          -  No morphological or functional cardiac valve/s changes, cardiac ischemia, significant&#xD;
             arrhythmias or in failure,&#xD;
&#xD;
          -  Patients with normal liver function tests before surgery and has no chronic active&#xD;
             liver disease,&#xD;
&#xD;
          -  Patients with normal kidney functions.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients with cardiac disease,&#xD;
&#xD;
          -  Kidney disease,&#xD;
&#xD;
          -  Liver dysfunction,&#xD;
&#xD;
          -  Those who receive additional blood products other than PRBCs.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yasser Hammad, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hamad Medical Corporation - HMC</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>yasser Hammad, M.D.</last_name>
    <phone>+97433000198</phone>
    <email>yhammad@hamad.qa</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Nabil Shallik, M.D.</last_name>
    <phone>+97455439264</phone>
    <email>nshallik@hamad.qa</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hamad Medical Corporation</name>
      <address>
        <city>Doha</city>
        <state>Ad Dawhah</state>
        <zip>3050</zip>
        <country>Qatar</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>yasser Hammad, M.D.</last_name>
      <phone>+974 3300 0198</phone>
      <email>yhammad@hamad.qa</email>
    </contact>
    <contact_backup>
      <last_name>Nabil Shallik</last_name>
      <phone>+97444393817</phone>
      <phone_ext>Shallik</phone_ext>
      <email>nshallik@hamad.qa</email>
    </contact_backup>
    <investigator>
      <last_name>Nabil Shallik, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Hazem Kassas, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Tarek Tageldin, MBBcH.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Qatar</country>
  </location_countries>
  <reference>
    <citation>Janeway CA Jr, Sharrow SO, Simpson E. T-cell populations with different functions. Nature. 1975 Feb 13;253(5492):544-6.</citation>
    <PMID>1078881</PMID>
  </reference>
  <reference>
    <citation>Greasley L, Russell RJ. Albumin and its role in trauma resuscitation. J R Army Med Corps. 2005 Jun;151(2):65-8. Review.</citation>
    <PMID>16097108</PMID>
  </reference>
  <reference>
    <citation>Ashraf S. Hasanin, Fatma M.A. Mahmoud, Hossam M. Soliman. Factors affecting acid base status during hepatectomy in cirrhotic patients. Egyptian Journal of Anesthesia (2013) 29, 305-310).</citation>
  </reference>
  <results_reference>
    <citation>Semin Thromb Hemost 1980; 6(2): 85-120 DOI: 10.1055/s-2007-1005097</citation>
  </results_reference>
  <results_reference>
    <citation>Peters T Jr. Serum albumin. Adv Protein Chem. 1985;37:161-245. Review.</citation>
    <PMID>3904348</PMID>
  </results_reference>
  <results_reference>
    <citation>Quinlan GJ, Martin GS, Evans TW. Albumin: biochemical properties and therapeutic potential. Hepatology. 2005 Jun;41(6):1211-9. Review.</citation>
    <PMID>15915465</PMID>
  </results_reference>
  <results_reference>
    <citation>Tullis JL. Albumin. 1. Background and use. JAMA. 1977 Jan 24;237(4):355-60 CONTD.</citation>
    <PMID>576167</PMID>
  </results_reference>
  <results_reference>
    <citation>Liumbruno GM, Bennardello F, Lattanzio A, Piccoli P, Rossettias G; Italian Society of Transfusion Medicine and Immunohaematology (SIMTI). Recommendations for the use of albumin and immunoglobulins. Blood Transfus. 2009 Jul;7(3):216-34. doi: 10.2450/2009.0094-09.</citation>
    <PMID>19657486</PMID>
  </results_reference>
  <results_reference>
    <citation>Pusey C, Dash C, Garrett M, Gascoigne E, Gesinde M, Gillanders K, Wallington T. Experience of using human albumin solution 4.5% in 1195 therapeutic plasma exchange procedures. Transfus Med. 2010 Aug 1;20(4):244-9. doi: 10.1111/j.1365-3148.2010.00999.x. Epub 2010 Mar 11.</citation>
    <PMID>20230532</PMID>
  </results_reference>
  <results_reference>
    <citation>Dill DB, Costill DL. Calculation of percentage changes in volumes of blood, plasma, and red cells in dehydration. J Appl Physiol. 1974 Aug;37(2):247-8.</citation>
    <PMID>4850854</PMID>
  </results_reference>
  <results_reference>
    <citation>Goodkin DA, Raja RM, Saven A. Dilutional acidosis. South Med J. 1990 Mar;83(3):354-5.</citation>
    <PMID>2315790</PMID>
  </results_reference>
  <results_reference>
    <citation>Mathes DD, Morell RC, Rohr MS. Dilutional acidosis: is it a real clinical entity? Anesthesiology. 1997 Feb;86(2):501-3.</citation>
    <PMID>9054271</PMID>
  </results_reference>
  <results_reference>
    <citation>Dunki-Jacobs EM, Philips P, Scoggins CR, McMasters KM, Martin RC 2nd. Stroke volume variation in hepatic resection: a replacement for standard central venous pressure monitoring. Ann Surg Oncol. 2014 Feb;21(2):473-8. doi: 10.1245/s10434-013-3323-9. Epub 2013 Oct 23.</citation>
    <PMID>24150192</PMID>
  </results_reference>
  <results_reference>
    <citation>Norberg Å, Rooyackers O, Segersvärd R, Wernerman J. Leakage of albumin in major abdominal surgery. Crit Care. 2016 Apr 26;20(1):113. doi: 10.1186/s13054-016-1283-8.</citation>
    <PMID>27117323</PMID>
  </results_reference>
  <results_reference>
    <citation>Nadler SB, Hidalgo JH, Bloch T. Prediction of blood volume in normal human adults. Surgery. 1962 Feb;51(2):224-32.</citation>
    <PMID>21936146</PMID>
  </results_reference>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>July 28, 2021</study_first_submitted>
  <study_first_submitted_qc>August 30, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">September 5, 2021</study_first_posted>
  <last_update_submitted>August 30, 2021</last_update_submitted>
  <last_update_submitted_qc>August 30, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Human Plasma Protein</keyword>
  <keyword>Crystalloids</keyword>
  <keyword>Liver Resection Surgeries</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Plasma protein fraction</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>A decision regarding sharing information will be taken at later stage</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_time_frame>Directly after IRB approval.</ipd_time_frame>
    <ipd_access_criteria>Website</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

